Loading...
Loading...
Momenta Pharmaceuticals
MNTA is trading lower on the session after announcing that Teva Pharmaceutical
TEVA received a favorable ruling in COPAXONE patent infringement case. The decision is subject to appeal.
Craig Wheeler, President and Chief Executive Officer of Momenta. "We are disappointed that the court determined that Teva's patents were valid and infringed, and we look forward to reading the full opinion to understand its reasoning. We remain confident in our legal position and we intend to appeal."
Momenta Pharmaceuticals is currently trading at $14.02, a loss of $2.99 or 17.61%.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Intraday UpdateMovers
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in